Expensive and unpleasant, but hepatitis C treatment is worth it, study shows

Research led by by Stanford Health Policy's Jeremy Goldhaber-Fiebert shows treatments for hepatitis C are cost-effective for patients with advanced disease. Their results are based on a computer model of hepatitis C.